• Andrea Chiricozzi, Anna Balato, Curdin Conrad, Andrea Conti, Paolo Dapavo, Paulo Ferreira, Francesca Maria Gaiani, Luiz Leite, Piergiorgio Malagoli, Pedro Mendes-Bastos, Matteo Megna, Francesco Messina, Alessia Nidegger, Giulia Odorici, Salvatore Panduri, Stefano Piaserico, Leonardo Piscitelli, Francesca Prignano, Simone Ribero, Joana Valerio, and Tiago Torres.
• Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
• J Dermatolog Treat. 2020 Aug 1; 31 (5): 476-483.

AbstractObjective: This European, multicentric, retrospective study aimed to collect data on secukinumab effectiveness in a real-world setting.Research design and methods: All psoriatic patients starting secukinumab between January 2016 and February 2017 in 11 European centers were followed until February 2018 and retrospectively evaluated.Main outcome measures: Secukinumab effectiveness was assessed by relative improvement from baseline of the Psoriasis Area Severity Index (PASI) and absolute PASI score modifications throughout 52 weeks of therapy. Additionally measures assessing effectiveness were used, including improvements of body surface area (BSA) and Dermatology Life Quality Index (DLQI).Results: Out of the 330 patients with potentially 52-week treatment duration, naïve to biologics patients showed greater probability to achieve PASI score of ≤1, ≤2, ≤3, and ≤5 at week 12, compared to bio-experienced patients (45.86% vs. 27.17%, 62.42% vs. 42.42%, 73.89% vs. 57.80%, and 84.08% vs. 74.57%, respectively). The greater effectiveness of secukinumab treatment in bio-naïve patients was confirmed at week 24 and 52.Conclusions: In this real-world experience, secukinumab was proven effective in treating psoriasis patients throughout a 52-weeks observation period, with higher response in bio-naïve patients. This study may contribute to defining the clinical profile of secukinumab best-responders.

23 keywords...

hide…